Siplizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Siplizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target CD2
Clinical data
Legal status ?
Identifiers
CAS number 288392-69-8 N
ATC code None
KEGG D05847 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]

References[edit]

  1. ^ ClinicalTrials.gov